Abstract
Platinum-based combinations constitute the backbone of chemotherapy in NSCLC. Furthermore, the regimens resulting from the addition of immunotherapy are considered the state of the art in treating advanced disease. Different platinum analogues are considered to exhibit similar activity; however, toxicity may differ. In an effort to identify these differences, we collected NSCLC patients’ reported data on side-effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
